Protocol

Time-restricted eating / intermittent fasting prescription

TRE · 16:8 · Intermittent fasting · Eating window · Time-restricted feeding · 12-hour window

Human RCT evidence is genuinely substantial: a live PubMed query returns 480 randomised controlled trials, 48 published in 2026 alone, including the TREAD trial (Obesity, 2026, PMID 42229885) and trials in PCOS, severe obesity and glycaemic control. This supports a "clinical" grade for short-term weight and metabolic outcomes. However, the honest reading is deflationary on three points. First, the weight loss appears largely attributable to spontaneous calorie reduction rather than to meal timing itself; head-to-head meta-analyses against continuous energy restriction (PMID 35565749, PMID 33293678, PMID 30583725) describe the comparative picture as controversial or uncertain rather than favouring TRE. Second, no trial demonstrates extension of healthspan or lifespan in humans; that claim is extrapolated from rodent and circadian-biology work and should not be presented as shown. Third, follow-up periods are mostly weeks to months, so durability is unestablished. A specific caution on commercial claims: Vively's page asserts 16:8 "can improve insulin sensitivity by 36-46%" without citing a source, and that precise figure should not be repeated as established. Practical risks (disordered-eating triggers, hypoglycaemia in patients on insulin or sulfonylureas, unsuitability in pregnancy) mean this warrants clinical supervision rather than blanket prescription. Note also that the first Vively URL supplied in discovery no longer contains any fasting language on live retrieval; only the second URL substantiates the claim.

At a glance

Evidence
Clinical
Singapore (HSA)
No HSA position on file
Australia (TGA)
No TGA position on file
Offered at
1 clinic

Singapore

Health Sciences Authority

HSA status
No position on file
In our SG set
Not tracked in Singapore
SG clinics
None on file

Australia

Therapeutic Goods Administration

TGA status
No position on file
In our AU set
Tracked in Australia
AU clinics
1
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.

What it is

Plain-language explainer

Time-restricted eating is a dietary timing protocol in which all food intake is confined to a fixed daily window, commonly 8 to 12 hours, with only water or non-caloric drinks outside it. The 16:8 pattern (16 hours fasting, 8 hours eating) is the most commonly prescribed variant. In longevity clinic settings it is prescribed as a behavioural intervention for metabolic health, typically alongside continuous glucose monitoring and dietitian coaching, and is claimed to improve insulin sensitivity, body composition and circadian metabolic alignment.

Categories

Protocol

Offered by

Where variis has verified this protocol (1)

Keep reading

Related coverage from the newsroom.

Global · Protocol

Global · Protocol

GLP-1s and healthspan: a 2026 reader’s primer

Suggest an updateJoin the community

Sources

What this profile is built on

  1. How to lose weight with insulin resistance · Vively (Australia)
  2. Longevity medicine in Australia: preventative care, technology and the future · Vively (Australia)
  3. Services and programmes · Chi Longevity (Singapore)
  4. Time-restricted eating randomised controlled trials (480 results) · PubMed, US National Library of Medicine
  5. Intermittent fasting versus continuous energy restriction meta-analyses · PubMed, US National Library of Medicine

Every entity profile on variis is sourced. Not medical advice.